Arvīds Irmejs

Arvīds Irmejs is an Associate Professor in the Department of Surgery at Rīga Stradiņš University (RSU) and Director of the Institute of Oncology and Molecular Genetics. He also serves as a Lead Researcher-Scientific Project Manager at RSU. His expertise spans hereditary breast and ovarian cancer genetics, clinical oncology, and cancer risk management. Dr. Irmejs holds prestigious roles including Corresponding Member of the Latvian Council of Science (since 2024) and multiple Expert appointments in Clinical and Basic Medicine (2016-2028).

Education and Academic Qualifications: Details not explicitly provided in the text but inferred from his roles. His research focuses on genetic screening strategies for hereditary cancers, with particular emphasis on BRCA1/BRCA2 mutations and genotype-phenotype correlations. He leads major projects like the 'Development of genetic testing strategies for hereditary breast and ovarian cancer risk prediction' (2024-2026), funded by the Recovery and Resilience Facility.

Research Interests: Breast and ovarian cancer genetics, cancer risk prediction, surgical outcomes in oncology, and implementation of genetic testing protocols. His work aligns with UN Sustainable Development Goals related to good health and well-being (SDG3).

Scientific Contributions: Over 76 publications since 2002, including high-impact studies on PTEN Hamartoma Tumor Syndrome and breast cancer prognosis. He actively participates in European reference networks like ERN GENTURIS and organizes academic events such as RSU Research Week 2025.

Awards and Recognition: Multiple appointments by the Latvian Council of Science reflect his national and international standing in oncology research. His work has been featured in media discussions on cancer care policies and fertility options post-treatment.